PlumX Metrics
Embed PlumX Metrics

Monoclonal antibodies for cancer immunotherapy

The Lancet, ISSN: 0140-6736, Vol: 373, Issue: 9668, Page: 1033-1040
2009
  • 264
    Citations
  • 0
    Usage
  • 287
    Captures
  • 2
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    264
  • Captures
    287
  • Mentions
    2
    • News Mentions
      1
      • News
        1
    • References
      1
      • Wikipedia
        1

Most Recent News

Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma; Inbraced

STUDY INFORMATION OFFICIAL TITLE: A Phase I Study of 131-1 Meta-iodobenzylguanidine (mIBG) Followed by Nivolumab and Chimeric 14.18 Anti-GD2 Monoclonal Antibody Produced in Chinese Hamster

Review Description

Monoclonal antibodies are effective treatments for many malignant diseases. However, the ability of antibodies to initiate tumour-antigen-specific immune responses has received less attention than have other mechanisms of antibody action. We describe the rationale and evidence for the development of antibodies that can stimulate host tumour-antigen-specific immune responses. Such responses can be induced through the induction of antibody-dependent cellular cytotoxicity, promotion of antibody-targeted cross-presentation of tumour antigens, or by triggering of the idiotypic network. Future treatment modifications or combinations might be able to prolong, amplify, and shape these immune responses to increase the clinical benefits of antibody therapy for human cancer.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know